Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children
<p>Abstract</p> <p>Background</p> <p>Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Tha...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-01-01
|
| Series: | BMC Research Notes |
| Online Access: | http://www.biomedcentral.com/1756-0500/3/29 |
| _version_ | 1818262057701605376 |
|---|---|
| author | Riewpaiboon Arthorn Nuchprayoon Issarang Torcharus Kitti Indaratna Kaemthong Thavorncharoensap Montarat Ubol Bang-on |
| author_facet | Riewpaiboon Arthorn Nuchprayoon Issarang Torcharus Kitti Indaratna Kaemthong Thavorncharoensap Montarat Ubol Bang-on |
| author_sort | Riewpaiboon Arthorn |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Thailand. The study was designed as a prevalence-based cost-of-illness analysis in a societal perspective. Medical records from three public hospitals of children aged 2-18 years with β-thalassemia/Hb E and homozygous β-thalassemia were reviewed for direct medical cost determination. For direct non-medical cost and indirect cost, a family member was interviewed.</p> <p>Findings</p> <p>It was found that 201 patients with β-thalassemia/Hb E (91%) and homozygous β-thalassemia (9%) were recruited for this study. Ninety-two (46%) were severe thalassemia and 109 (54%) were mild to moderate severity. The annual average cost of treatment was US$950; 59% was direct medical cost, 17% direct non-medical cost, and 24% indirect cost. The costs were differentiated by some potential predictors. Significant predictor variables were: hospital, health insurance scheme, blood transfusion pattern, and iron chelation drug use.</p> <p>Conclusions</p> <p>The average annual cost per patient was calculated, and the cost model was estimated. These would be applied for national planning, economic evaluation of treatment and prevention interventions, and budget impact analysis.</p> |
| first_indexed | 2024-12-12T18:57:04Z |
| format | Article |
| id | doaj.art-e0ac27fdc1a04bdbb1963791384ba467 |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-12-12T18:57:04Z |
| publishDate | 2010-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-e0ac27fdc1a04bdbb1963791384ba4672022-12-22T00:15:12ZengBMCBMC Research Notes1756-05002010-01-01312910.1186/1756-0500-3-29Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai childrenRiewpaiboon ArthornNuchprayoon IssarangTorcharus KittiIndaratna KaemthongThavorncharoensap MontaratUbol Bang-on<p>Abstract</p> <p>Background</p> <p>Hemoglobin E beta-thalassemia (β-thalassemia/Hb E) has a variable severity, and the cost of treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children with β-thalassemias in Thailand. The study was designed as a prevalence-based cost-of-illness analysis in a societal perspective. Medical records from three public hospitals of children aged 2-18 years with β-thalassemia/Hb E and homozygous β-thalassemia were reviewed for direct medical cost determination. For direct non-medical cost and indirect cost, a family member was interviewed.</p> <p>Findings</p> <p>It was found that 201 patients with β-thalassemia/Hb E (91%) and homozygous β-thalassemia (9%) were recruited for this study. Ninety-two (46%) were severe thalassemia and 109 (54%) were mild to moderate severity. The annual average cost of treatment was US$950; 59% was direct medical cost, 17% direct non-medical cost, and 24% indirect cost. The costs were differentiated by some potential predictors. Significant predictor variables were: hospital, health insurance scheme, blood transfusion pattern, and iron chelation drug use.</p> <p>Conclusions</p> <p>The average annual cost per patient was calculated, and the cost model was estimated. These would be applied for national planning, economic evaluation of treatment and prevention interventions, and budget impact analysis.</p>http://www.biomedcentral.com/1756-0500/3/29 |
| spellingShingle | Riewpaiboon Arthorn Nuchprayoon Issarang Torcharus Kitti Indaratna Kaemthong Thavorncharoensap Montarat Ubol Bang-on Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children BMC Research Notes |
| title | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
| title_full | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
| title_fullStr | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
| title_full_unstemmed | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
| title_short | Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children |
| title_sort | economic burden of beta thalassemia hb e and beta thalassemia major in thai children |
| url | http://www.biomedcentral.com/1756-0500/3/29 |
| work_keys_str_mv | AT riewpaiboonarthorn economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT nuchprayoonissarang economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT torcharuskitti economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT indaratnakaemthong economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT thavorncharoensapmontarat economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren AT ubolbangon economicburdenofbetathalassemiahbeandbetathalassemiamajorinthaichildren |